Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations

PURPOSE: The high expense of newer, more effective adjuvant endocrine therapy agents (aromatase inhibitors [AIs]) for postmenopausal breast cancer contributes to socioeconomic disparities in breast cancer outcomes. This study compares endocrine therapy costs for breast cancer patients during the fir...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Springerplus
Egile Nagusiak: Nattinger, Ann Butler, Pezzin, Liliana E, McGinley, Emily L, Charlson, John A, Yen, Tina W F, Neuner, Joan M
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer International Publishing 2015
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4320689/
https://ncbi.nlm.nih.gov/pubmed/25674506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-015-0827-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak